Navigation Links
ARIUS announces manufacturing agreement with Avid Bioservices for CD44 Cancer Stem Cell antibody
Date:12/5/2007

- Pre-IND meeting with FDA scheduled for January for lead antibody program

-

TORONTO, Dec. 5 /PRNewswire-FirstCall/ - ARIUS Research Inc. (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced that it has entered into a manufacturing supply and technology transfer agreement for its CD44 Cancer Stem Cell antibody with Avid Bioservices, a company providing cGMP manufacturing services for the biotechnology and biopharmaceutical industries. Avid has begun manufacturing a supply of the drug for human clinical trials which ARIUS plans to initiate in 2008. ARIUS also announced it has scheduled a pre-IND meeting with the FDA that will take place in January.

"The initiation of manufacturing and the scheduling of our pre-IND meeting with the FDA in January reflect the significant progress we have made with our CD44 Cancer Stem Cell program," said Dr. David Young, President and Chief Executive Officer of ARIUS. "Avid has proven expertise in the scale-up and manufacture of clinical and commercial grade antibodies and will provide us with a supply of our CD44 targeting drug to initiate human clinical trials in 2008, subject to the clearance of our IND by the FDA."

"This new manufacturing agreement is the result of the solid working relationship we have developed with the ARIUS team," said F. David King, Vice President, Business Development of Avid. "Our goal is to form strategic partnerships with innovative life sciences companies like ARIUS, serving as a premier service provider by seamlessly integrating our experience and capabilities with our clients' needs."

ARIUS is advancing the formal pre-clinical toxicology program for its lead CD44 Cancer Stem Cell program, an anti-cancer antibody targeting a novel epitope of CD44 found in breast, colon, and prostate cancers. Pre-clinical data from a dose-ranging pilot toxicology study in non-human prima
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
2. ARIUS Announces Third Quarter Fiscal 2007 Financial Results
3. Arius highlighted at AACR-NCI-EORTC 2007 International Cancer Conference
4. ARIUS to present at Chinese Global Financial Forum
5. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
6. Arius announces new findings in Trop-2 and CD59 CANCER antibody programs
7. ARIUS to present at BioNorth Biotechnology and Life Sciences Conference
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
10. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
11. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014 Five American winners ... Al Maktoum Awards for Medical Sciences", in its 8 ... Arab Emirates , on 15 December 2014. ... The Carter Center which won the Hamdan Award ... in numerous programs that aim to improve health and ...
(Date:11/24/2014)... , Nov. 24, 2014 VolitionRx Limited ... tests for cancer and other conditions, today announced that data ... the Science for Business BioWin Day 2014, being held November ... data come from VolitionRx,s lung cancer pilot study, the samples ... Centre Hospitalier Universitaire (CHU) de Liege in Belgium ...
(Date:11/24/2014)... 2014   Veracyte, Inc. (Nasdaq: VCYT ... and chief executive officer, will present in a fireside chat ... Conference on Tuesday, December 2, 2014 at 12:30 p.m. ET ... live audio webcast and subsequent replay may be accessed by ... the website at least 15 minutes prior to the live ...
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) ... trials at its mid-Atlantic late-phase research facility, located ... with the idea of closing patient disparities in ... medical advances," said Continental's CEO, Saleh Stevens ... immortal cell line of Henrietta Lacks, dubious ethical ...
Breaking Biology Technology:Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... 21, 2011 MDOUTLOOK®, the global oncology intelligence initiative ... Annual Quick Poll research launched immediately following this month,s ... (ASCO) in Chicago. These Quick Polls expand on previous ... annual meetings, as well as similar efforts after the ...
... 21, 2011 Waife & Associates, Inc. (W&A), change ... is adding the consulting practice of Mark Di Ianni, ... Di Ianni has been a senior executive in the ... and/or managing a series of successful companies. In recent ...
... ROCKVILLE, Md., June 21, 2011 For successful ... needs to be aligned from concept through the ... (RAPS)webinar, participants will learn why Regulatory and Marketing ... product claims and promote the product for both ...
Cached Biology Technology:MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics 2MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics 3Waife & Associates, Inc. Adds Mark Di Ianni as Principal Consultant 2How-To RAPS Webinar June 30: Regulatory and Marketing Symbiosis from Concept to Launch 2
(Date:11/21/2014)... C-Labs LLC, a leading provider of remote ... today announced the appointment of John Traynor ... strategic advisor to the firm, Mr. Traynor will now ... based out of the C-Labs office in ... Muench , Chief Executive Officer. Photo - ...
(Date:11/18/2014)... , Nov. 18, 2014   EyeLock ... authentication solutions, and MorphoTrust USA (Safran), ... services, today announced a strategic partnership to offer ... motor vehicle administration (MVA), airport screening and financial ... identity-related solutions, MorphoTrust serves consumers through a nationwide ...
(Date:11/7/2014)... Researchers led by Dr. Debra Auguste, associate professor, ... at The City College of New York, have ... treatment for one of the most aggressive forms ... (TNBCs) have a high mortality rate owing to ... effective therapeutic options. However, Professor Auguste,s team, discovered ...
Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
... MADISON, WI, SEPTEMBER 2, 2008 Varying the rate of ... intuitive sense, as farmers have long observed differences in ... The availability of spatial yield information from combines equipped ... improved management. So, optimizing inputs to match ...
... biomarkers for the detection of diseases including cancer and ... Cell Research . The findings pave the way ... are a class of naturally occurring small non-coding RNAs ... reporting individual miRNAs as diagnostic biomarkers of specific cancers ...
... University nanophotonics pioneer Naomi Halas has won one of ... the University of Pennsylvania,s Nano/Bio Interface Center (NBIC). ... the innovative synthesis of nanostructures. She will accept the ... ceremonies Oct. 29 in Philadelphia. Halas is the ...
Cached Biology News:A little nitrogen can go a long way 2A little nitrogen can go a long way 3
UltraMount is formulated for coverslipping sections stained with alcohol soluble chromogens, such as Fast-Red or AEC. No heating is required prior to use. Coverslips may be removed by soaking in wate...
AM100 is an aqueous-based, permanent mounting media designed for use with alkaline phosphatase and immunoperoxidase stained tissue sections....
...
... Fixation Buffer, used in conjunction with ... can be used to fix and ... staining of cytokines and other cytoplasmic ... been specially formulated for reducing non-specific ...
Biology Products: